Search

Table S3. Year wise rotavirus genotype distribution across 7 sites. The file contains details of year wise distribution of rotavirus genotypes in children with acute gastroenteritis in India across 7 sites. (DOCX 19 kb)

Table S2. Association between rotavirus genotype and severity of diarrhoea. The file contains details of the six common rotavirus genotypes in this study, and their association with severity of diarrhoea in children

Table S1. List of excluded cases. The list contains details of reasons for site wise exclusion of cases from final analysis. (DOCX 16 kb)

Table S5. Rotavirus genotype distribution in south Indian sites. The file contains details of year wise distribution of rotavirus genotypes in the 5 south Indian sites from July 2012 to June 2016. (DOCX 20 kb)

Table S4. Rotavirus genotype distribution in north Indian sites. The file contains details of year wise distribution of rotavirus genotypes in the 2 north Indian sites from July 2012 to June 2016. (DOCX 20 kb)

In this study, the potential of RGB color imaging to detect fungal contamination in three varieties (Khalas, Fard and Naghal) of dates was investigated. The samples were treated as three groups: UC (untreated control), SC (surface sterilized, rinsed and air-dried) and IS (surface sterilized, rinsed, air-dried and fungal inoculated). Color images of control samples and A. flavus inoculated date fruits after every 48 h of inoculation for 10 days were acquired using an RGB color imaging system (n=3150). The classification accuracies for IS were compared with UC and SC separately using a two-class model (control vs. infected (all stages of infection together)), six-class model (control, infected day 2, day 4, day 6, day 8 and day 10) and pair-wise model (control vs. each stage of infection). In the two-class model, the highest accuracy obtained by Fard, Khalas and Naghal dates were 97, 100 and 99%, respectively. The developed algorithm was also tested on pooled dates (all three varieties were combined together: control vs infected), and 98% and 99% of infested samples were correctly classified from untreated control and sterile control, respectively in two class models. In six class models, highest classification accuracies of 99-100% were obtained for IS Day 10 in all three date varieties.

Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous group of disorders. A particularly severe subgroup first described in 1894, and subsequently called Brown-Vialetto-Van Laere syndrome, is characterized by progressive pontobulbar palsy, sensorineural hearing loss and respiratory insufficiency. There has been no treatment for this progressive neurodegenerative disorder, which leads to respiratory failure and usually death during childhood. We recently reported the identification of SLC52A2, encoding riboflavin transporter RFVT2, as a new causative gene for Brown-Vialetto-Van Laere syndrome. We used both exome and Sanger sequencing to identify SLC52A2 mutations in patients presenting with cranial neuropathies and sensorimotor neuropathy with or without respiratory insufficiency. We undertook clinical, neurophysiological and biochemical characterization of patients with mutations in SLC52A2, functionally analysed the most prevalent mutations and initiated a regimen of high-dose oral riboflavin. We identified 18 patients from 13 families with compound heterozygous or homozygous mutations in SLC52A2. Affected individuals share a core phenotype of rapidly progressive axonal sensorimotor neuropathy (manifesting with sensory ataxia, severe weakness of the upper limbs and axial muscles with distinctly preserved strength of the lower limbs), hearing loss, optic atrophy and respiratory insufficiency. We demonstrate that SLC52A2 mutations cause reduced riboflavin uptake and reduced riboflavin transporter protein expression, and we report the response to high-dose oral riboflavin therapy in patients with SLC52A2 mutations, including significant and sustained clinical and biochemical improvements in two patients and preliminary clinical response data in 13 patients with associated biochemical improvements in 10 patients. The clinical and biochemical responses of this SLC52A2-specific cohort suggest that riboflavin supplementation can ameliorate the progression of this neurodegenerative condition, particularly when initiated soon after the onset of symptoms.